IVIG Privigen denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits Privigen Quantities — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) is a high-cost biologic administered by infusion, and Humana's coverage policy sets quantity limits that govern how much product can be dispensed or authorized per treatment cycle. A quantity-limits denial means your prescription or infusion order exceeded the amount Humana will approve without additional justification. This is one of the most successfully overturned denial types when the medical record documents why the standard allotment is insufficient for your specific clinical situation.

## Why This Denial Is Appealable

Quantity limits are not clinical verdicts — they are administrative defaults designed around average patients. If your prescriber has determined that your diagnosis, body weight, disease severity, or infusion schedule requires a different amount than the default, that individualized clinical rationale is grounds for override. Humana must evaluate appeals on their individual merits and cannot apply a blanket quantity rule when documented medical necessity supports a different quantity.

## Federal Appeal Framework

• ERISA §503 (employer plans): Entitles you to a full-and-fair review with access to the clinical criteria used.
• ACA §2719 / State external review: After exhausting internal levels, you may request independent external review. The standard window is approximately four months from the original denial notice, so act promptly.
• Expedited review: If your condition is urgent or your infusion schedule is imminent, request expedited review at every level — timelines compress from weeks to days.

## Your Appeal Process

1. Request the denial letter and Humana's Privigen quantity-limit policy in writing. 2. File a Level 1 internal appeal within the timeframe printed on your denial notice. 3. If upheld, file Level 2 (if available under your plan) or proceed directly to external review. 4. Request an expedited track if clinical urgency applies.

## Documentation to Gather

• Diagnosis confirmation: Specialist notes establishing your FDA-recognized indication for Privigen (e.g., primary immunodeficiency, CIDP, or other labeled condition).
• Body-weight and dosing rationale: Your prescriber's calculation showing why the quantity ordered is medically necessary — reference the FDA-approved prescribing information for the approved dosing range for your indication.
• Infusion schedule: Frequency and interval prescribed, with clinical rationale if it differs from a standard interval.
• Prior infusion records: Dates, quantities administered, and clinical response (or lack of response at lower amounts).
• Medical-necessity letter: Your prescriber should explicitly state why the quantity limit is clinically inappropriate for you and cite the relevant guideline organization (e.g., applicable IUIS or AAI guidance) without inventing statistics.

## Criteria-Mapping Strategy

Obtain Humana's published medical/coverage policy for Privigen and the FDA-approved prescribing label. List every quantity criterion in the policy, then document point-by-point how your chart satisfies each one. If your required quantity falls outside the default, your prescriber's letter must explain the clinical reason (e.g., weight-based calculation, poor trough response at standard dose). A structured table — policy criterion on the left, your chart evidence on the right — is the most persuasive appeal format.